Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tumor marker expression is predictive of survival in patients with esophageal cancer  Thomas A Aloia, MD, David H Harpole, MD, Carolyn E Reed, MD, Carmen.

Published byColeen Williams Modified over 6 years ago

Similar presentations

Presentation on theme: "Tumor marker expression is predictive of survival in patients with esophageal cancer  Thomas A Aloia, MD, David H Harpole, MD, Carolyn E Reed, MD, Carmen."— Presentation transcript:

1 Tumor marker expression is predictive of survival in patients with esophageal cancer 
Thomas A Aloia, MD, David H Harpole, MD, Carolyn E Reed, MD, Carmen Allegra, PhD, Mary-Beth H Moore, BA, James E Herndon, PhD, Thomas A D’Amico, MD  The Annals of Thoracic Surgery  Volume 72, Issue 3, Pages (September 2001) DOI: /S (01)

2 Fig 1 Representative samples of immunohistochemically stained esophageal tumor specimens. Areas of brown coloration indicate immunohistochemical marker staining. Antibodies included are (clockwise from upper left) p53, Her2-neu, glutathione S-transferase-π, and P-glycoprotein. All photomicrographs were imaged at ×40. (GST-π = glutathione S-transferase-π; P-gp = p-glycoprotein.) The Annals of Thoracic Surgery  , DOI: ( /S (01) )

3 Fig 2 Cancer-specific survival analysis for the entire cohort plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. The Annals of Thoracic Surgery  , DOI: ( /S (01) )

4 Fig 3 Cancer-specific survival analysis comparing patients with T1, T2, and T3 esophageal tumors plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. The Annals of Thoracic Surgery  , DOI: ( /S (01) )

5 Fig 4 (A) Cancer-specific survival analysis comparing patients with low-level expression of P-glycoprotein (P-gp) versus those with P-glycoprotein high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. (B) Cancer-specific survival analysis comparing patients with low-level expression of transforming growth factor-α (TGF-α) versus those with transforming growth factor-α high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. (C) Cancer-specific survival analysis comparing patients with low-level expression of glutathione S-transferase-π (GST-π) versus those with glutathione S-transferase-π high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. (D) Cancer-specific survival analysis comparing patients with low-level expression of p53 versus those with p53 high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. (E) Cancer-specific survival analysis comparing patients with low expression of factor VIII versus those with factor VIII high-level expression, plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. Number of patients at risk at 1-, 3-, and 5-year intervals is given along the x-axis. The Annals of Thoracic Surgery  , DOI: ( /S (01) )

6 Fig 5 Cancer-specific survival analysis comparing patient groups determined by the number of negative prognostic markers present (0, 1 to 2, 3, and 4 markers), plotted as percent survival versus time in months (mo.) using the Kaplan-Meier product limit estimator. The Annals of Thoracic Surgery  , DOI: ( /S (01) )

Download ppt "Tumor marker expression is predictive of survival in patients with esophageal cancer  Thomas A Aloia, MD, David H Harpole, MD, Carolyn E Reed, MD, Carmen."

Similar presentations

Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer  Wu-Wei Lai, MD, Fen-Fen Chen, MD,

Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer  Wu-Wei Lai, MD, Fen-Fen Chen, MD,
Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease  Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,

Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease  Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,
Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment  William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment  William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.
High Risk of Prosthetic Valve Endocarditis and Death After Valve Replacement Operations in Dialysis Patients  Danielle K. Farrington, MD, Patrick D. Kilgo,

High Risk of Prosthetic Valve Endocarditis and Death After Valve Replacement Operations in Dialysis Patients  Danielle K. Farrington, MD, Patrick D. Kilgo,
Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,
Leena Khaitan, MD, Francis P Sutter, Scott M Goldman, MD 

Leena Khaitan, MD, Francis P Sutter, Scott M Goldman, MD 
Jeevan Nagendran, MD, Colleen M. Norris, PhD, Michelle M

Jeevan Nagendran, MD, Colleen M. Norris, PhD, Michelle M
Clinicopathological and biological assessment of lung cancers with pleural dissemination  Yasuhiko Ohta, MD, Yoko Tanaka, PhD, Takuo Hara, MD, Makoto.

Clinicopathological and biological assessment of lung cancers with pleural dissemination  Yasuhiko Ohta, MD, Yoko Tanaka, PhD, Takuo Hara, MD, Makoto.
Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E

Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E
Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability?  Tirone E. David, MD, Susan Armstrong, MS,

Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability?  Tirone E. David, MD, Susan Armstrong, MS,
Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers  Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers  Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.
Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Puja Gaur, MD, Wayne L. Hofstetter, MD, B
Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer  Lars P. Riber, MD, PhD, Thomas D. Christensen,

Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer  Lars P. Riber, MD, PhD, Thomas D. Christensen,
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Complications and Risk Assessment of 25 Years in Pediatric Pacing

Complications and Risk Assessment of 25 Years in Pediatric Pacing
Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung  Kenzo Hiroshima, MD, Akira Iyoda, MD, Kiyoshi Shibuya, MD, Tetsuya.

Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung  Kenzo Hiroshima, MD, Akira Iyoda, MD, Kiyoshi Shibuya, MD, Tetsuya.
Log Odds of Positive Lymph Nodes Predicts Survival in Patients After Resection for Esophageal Cancer  Jinlin Cao, MD, Ping Yuan, MD, Honghai Ma, MD, Peng.

Log Odds of Positive Lymph Nodes Predicts Survival in Patients After Resection for Esophageal Cancer  Jinlin Cao, MD, Ping Yuan, MD, Honghai Ma, MD, Peng.
Surgery for coarctation of the aorta in infants weighing less than 2 kg  Emile A Bacha, MD, Melvin Almodovar, MD, David L Wessel, MD, David Zurakowski,

Surgery for coarctation of the aorta in infants weighing less than 2 kg  Emile A Bacha, MD, Melvin Almodovar, MD, David L Wessel, MD, David Zurakowski,
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.
Tumor Angiogenesis as a Prognostic Marker in Operable Non–Small Cell Lung Cancer  Katsuhiko Matsuyama, Yukio Chiba, Masato Sasaki, Hirokazu Tanaka, Ryusuke.

Tumor Angiogenesis as a Prognostic Marker in Operable Non–Small Cell Lung Cancer  Katsuhiko Matsuyama, Yukio Chiba, Masato Sasaki, Hirokazu Tanaka, Ryusuke.

Similar presentations

Ads by Google